SCHEMBL16629610

SCHEMBL16629610

c1ccc(-n2c3ccccc3c3ccc4c5ccccc5n(-c5cccc(-c6cccc7ccc8cccnc8c67)c5)c4c32)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.36
KDM4E B2RXH2 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ATM Q13315 1/20 0.35
FABP1 P07148 1/20 0.35
TSHR P16473 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 3/20 0.35
CCR1 P32246 3/20 0.34
CCR5 P51681 3/20 0.34
CCR8 P51685 3/20 0.34
MAPT P10636 3/20 0.34
TP53 P04637 2/20 0.34
MMP2 P08253 2/20 0.34
LMNA P02545 2/20 0.34
GMNN O75496 1/20 0.34
HSP90AA1 P07900 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16629622 0.91 METAP2 (0.39) METAP2KDM4EL3MBTL1ATMFABP1
SCHEMBL16629631 0.88 KDM4E (0.38) METAP2KDM4EL3MBTL1ATMFABP1
SCHEMBL16629609 0.86 CCR1 (0.35) METAP2KDM4EL3MBTL1ATMFABP1
SCHEMBL15930417 0.86 KDM4E (0.36) METAP2KDM4EL3MBTL1ATMTSHR
SCHEMBL17248277 0.85 METAP2 (0.39) METAP2KDM4EL3MBTL1ATMFABP1
SCHEMBL16629623 0.85 ALK (0.36) METAP2KDM4EL3MBTL1ATMFABP1
SCHEMBL16629629 0.84 KDM4E (0.41) KDM4EL3MBTL1ATMTSHRALDH1A1
SCHEMBL16483609 0.84 FABP1 (0.37) METAP2KDM4EL3MBTL1FABP1TSHR
SCHEMBL17946241 0.82 METAP2 (0.36) METAP2KDM4EL3MBTL1ATMFABP1
SCHEMBL17245385 0.81 L3MBTL1 (0.50) KDM4EL3MBTL1ATMALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices MERCK PATENT GMBH (DE) 2019-09-10 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
WO-2015049022-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES KCNQ1, KCNH1, KCNQ2 METAP2 3484/4885KDM4E 1939/4885L3MBTL1 2372/4885
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices KCNQ1, KCNH1, KCNQ2 METAP2 3484/4885KDM4E 1939/4885L3MBTL1 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.